| Literature DB >> 32091363 |
Chuan-Chin Huang, Alexander L Chu, Mercedes C Becerra, Jerome T Galea, Roger Calderón, Carmen Contreras, Rosa Yataco, Zibiao Zhang, Leonid Lecca, Megan B Murray.
Abstract
Few studies have prospectively compared the relative transmissibility and propensity to cause disease of Mycobacterium tuberculosis Beijing strains with other human-adapted strains of the M. tuberculosis complex. We assessed the effect of Beijing strains on the risk for M. tuberculosis infection and disease progression in 9,151 household contacts of 2,223 culture-positive pulmonary tuberculosis (TB) patients in Lima, Peru. Child contacts exposed to Beijing strains were more likely than child contacts exposed to non-Beijing strains to be infected at baseline, by 12 months of follow-up, and during follow-up. We noted an increased but nonsignificant tendency for child contacts to develop TB. Beijing strains were not associated with TB in adult contacts. These findings suggest that Beijing strains are more transmissible in children than are non-Beijing strains.Entities:
Keywords: BCG vaccine; Mycobacterium tuberculosis; Peru; Tuberculosis; bacteria; infection transmission; latent tuberculosis infection; tuberculosis and other mycobacteria
Mesh:
Year: 2020 PMID: 32091363 PMCID: PMC7045848 DOI: 10.3201/eid2603.191314
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Baseline characteristics of Mycobacterium tuberculosis culture-positive index patients, Lima, Peru, September 2009–August 2012
| Variable | No. (%), N = 2,223* |
|---|---|
| Age, y | |
| 16–30 | 1,363 (61) |
| 31–45 | 465 (21) |
|
| 395 (18) |
| Sex | |
| M | 1,289 (58) |
| F | 934 (42) |
| Concurrent condition | |
| HIV seropositive | 59 (3) |
| Self-reported diabetes | 111 (6) |
| Current smoker | 60 (3) |
| L2 (Beijing) | 255 (12) |
| L4.1 | 951 (43) |
| L4.3 | 775 (35) |
| Other | 242 (11) |
| Sputum smear status† | |
| Negative | 548 (25) |
| + | 639 (29) |
| ++ | 431 (19) |
| +++ | 596 (27) |
| Cavitary disease | 655 (30) |
| Drug resistance profile | |
| Pansusceptible | 1,442 (67) |
| Resistant | 726 (33) |
*Numbers might not add to total because of missing data. †+, 1–99 acid-fast bacilli (AFB) in 100 observed fields; ++, 1–10 AFB per field in 50 observed fields; +++, >10 AFB per field in 20 observed fields.
Baseline characteristics of household contacts exposed to a Mycobacterium tuberculosis culture-positive index tuberculosis patient, Lima, Peru, September 2009–August 2012
| Variable | Total no. (%), N = 9,151* | Age | Age >15 y, no. (%) |
|---|---|---|---|
| Age, y | |||
|
| 3,225 (35) | 3,225 (100) | Not applicable |
| >15 | 5,926 (65) | Not applicable | 5,926 (100) |
| Sex | |||
| M | 4,147 (45) | 1,620 (50) | 2,527 (43) |
| F | 5,004 (55) | 1,605 (50) | 3,399 (53) |
| Concurrent condition | |||
| HIV seropositive | 33 (<1) | 3 (<1) | 30 (1) |
| Self-reported diabetes | 165 (2) | 2 (<1) | 163 (3) |
| Current smoker | 559 (6) | 4 (<1) | 555 (10) |
| L2 (Beijing) | 1,041 (11) | 349 (11) | 692 (12) |
| L4.1 | 3,733 (41) | 1,332 (41) | 2,401 (41) |
| L4.3 | 3,416 (37) | 1,202 (37) | 2,214 (37) |
| Other | 961 (11) | 342 (11) | 619 (10) |
| Presence of | 8,110 (89) | 2,876 (89) | 5,253 (89) |
| Nutritional status | |||
| Normal weight | 5,261 (58) | 2,527 (79) | 2,734 (47) |
| Underweight | 163 (2) | 95 (3) | 68 (1) |
| Overweight | 3,636 (40) | 565 (18) | 3,071 (52) |
| Socioeconomic status | |||
| Low | 3,112 (35) | 1,253 (40) | 1,859 (33) |
| Middle | 3,991 (45) | 1,384 (44) | 2,607 (45) |
| High | 1,828 (21) | 514 (16) | 1,314 (23) |
| Isoniazid preventive therapy recipient | 2,090 (23) | 1,542 (48) | 490 (7) |
*Numbers might not add to total because of missing data.
Effect of the Mycobacterium tuberculosis Beijing lineage on the risk for infection at baseline in child and adult household contacts of culture-positive index patients, Lima, Peru, September 2009–August 2012
| Lineage | Age |
| Age >15 y, n = 5,663 | ||||
| Prevalence, no. (%)† | Risk ratio (95% CI) | Prevalence, no. (%)† | Risk ratio (95% CI) | ||||
| Univariate | Multivariate‡ | Univariate | Multivariate‡ | ||||
| Non-Beijing | 731 (26) | Referent | Referent |
| 2,654 (53) | Referent | Referent |
| Beijing | 110 (33) | 1.27 (1.06–1.53) | 1.23 (1.02–1.50) | 353 (53) | 0.99 (0.91–1.08) | 1.00 (0.91–1.09) | |
*Likelihood ratio test for the interaction between age (15 or >15) and index patient M. tuberculosis lineage: p = 0.025. †Prevalence of baseline M. tuberculosis infection in the univariate model. ‡Multivariate model adjusted for index patient drug resistance profile; index patient age (16–30, 31–45, 46–60, and >60 y); index patient HIV status; household contact age (0–5, 6–10, 11–15, 16–30, 31–45, 46–60, and >60 y); household contact M. bovis BCG vaccination status; household contact socioeconomic status; household contact nutritional status.
Effect of the Mycobacterium tuberculosis Beijing lineage on the risk for infection by 12 months of follow-up in child and adult household contacts of culture-positive index patients, Lima, Peru, September 2009–August 2012
| Lineage | Age |
| Age >15 y, n = 4,921* | ||||
| Prevalence, no. (%)† | Risk ratio (95% CI) | Prevalence, no. (%)† | Risk ratio (95% CI) | ||||
| Univariate | Multivariate‡ | Univariate | Multivariate‡ | ||||
| Non-Beijing | 1,098 (49) | Referent | Referent | 3,546 (82) | Referent | Referent | |
| Beijing | 173 (59) | 1.20 (1.08–1.35) | 1.22 (1.09–1.38) | 474 (82) | 1.00 (0.96–1.05) | 1.01 (0.97–1.06) | |
*Likelihood ratio test for the interaction between age (<15 or >15 y) and index patient M. tuberculosis lineage: p = 0.003. †Prevalence of M. tuberculosis infection by 12 months for the univariate model. ‡Adjusted for index patient drug resistance profile; index patient age (16–30, 31–45, 46–60, and >60 y); index patient HIV status; household contact age (0–5, 6–10, 11–15, 16–30, 31–45, 46–60, and >60 y); household contact M. bovis BCG vaccination status; household contact socioeconomic status; household contact nutritional status.
Hazard ratios of tuberculin skin test conversion comparing contacts exposed to a Mycobacterium tuberculosis Beijing lineage with those exposed to a non-Beijing lineage, Lima, Peru, September 2009–August 2012
| Lineage | Age | Age >15 y* | |||||
|---|---|---|---|---|---|---|---|
| Incidence, %† | Hazard ratio (95% CI) | Incidence, %† | Hazard ratio (95% CI) | ||||
| Univariate | Multivariate‡ | Univariate | Multivariate‡ | ||||
| Non-Beijing | 0.26 (356/1,396) | Referent | Referent | 0.69 (845/1,236) | Referent | Referent | |
| Beijing | 0.39 (62/160) | 1.53 (1.09–2.14) | 1.65 (1.17–2.33) | 0.73 (118/162) | 1.02 (0.80–1.30) | 1.03 (0.80–1.33) | |
*Likelihood ratio test for the interaction between age (<15 or >15 y) and index patient M. tuberculosis lineage: p = 0.048. †Per person-year for the univariate model. ‡Adjusted for index patient drug resistance profile; index patient age (16–30, 31–45, 46–60, and >60 y); index patient HIV status; household contact age (0–5, 6–10, 11–15, 16–30, 31–45, 46–60, and >60 y); household contact M. bovis BCG vaccination status; household contact socioeconomic status; household contact nutritional status.
Figure 1Survival curves for incident Mycobacterium tuberculosis infection in child household contacts by index patient M. tuberculosis lineage, Lima, Peru, September 2009–August 2012.
Figure 2Survival curves for incident Mycobacterium tuberculosis infection in adult household contacts by index patient M. tuberculosis lineage, Lima, Peru, September 2009–August 2012.
Hazard ratios of incident tuberculosis among contacts exposed to a Mycobacterium tuberculosis Beijing lineage and a non-Beijing lineage, Lima, Peru, September 2009–August 2012
| Lineage | Age |
| Age >15 y* | |||||
| Incidence, %† | Hazard ratio (95% CI) | Incidence, %† | Hazard ratio (95% CI) | |||||
| Univariate | Multivariate‡ | Univariate | Multivariate‡ | |||||
| Non-Beijing | 3,043 (84/2,760) | Referent | Referent | 2,874 (156/4,993) | Referent | Referent | ||
| Beijing | 4,478 (15/335) | 1.42 (0.78–2.59) | 1.45 (0.77–2.72) | 3,124 (19/661) | 0.93 (0.57–1.52) | 1.06 (0.64–1.77) | ||
*Likelihood ratio test for the interaction between age (<15 or >15 y) and index patient M. tuberculosis lineage: p = 0.231. †Per 100,000 person-years in the univariate model. ‡Adjusted for index patient drug resistance profile; index patient age (16–30, 31–45, 46–60, and >60 y); index patient HIV status; household contact age (0–5, 6–10, 11–15, 16–30, 31–45, 46–60, and >60 y); household contact M. bovis BCG vaccination status; household contact SES; household contact nutritional status; household contact use of isoniazid preventive therapy; household contact TB history.
Figure 3Survival curves for incident tuberculosis in child household contacts by index patient Mycobacterium tuberculosis lineage, Lima, Peru, September 2009–August 2012.
Figure 4Survival curves for incident tuberculosis in adult household contacts by index patient Mycobacterium tuberculosis lineage, Lima, Peru, September 2009–August 2012.
Effects of BCG vaccination on M. tuberculosis infection and TB outcomes by lineage exposure for child and adult household contacts of culture-positive pulmonary tuberculosis patients, Lima, Peru, September 2009–August 2012*
| Category and BCG vaccination status | Non-Beijing lineage |
| Beijing lineage | p value | ||
| Infection prevalence, no. (%) | RR (95% CI) | Infection prevalence, no. (%) | RR (95% CI) | |||
| Children, |
|
|
|
|
|
|
| Baseline |
|
|
|
| 0.691 | |
| Without BCG vaccination | 137 (27) | Referent |
| 19 (32) | Referent |
|
| With BCG vaccination | 552 (26) | 0.94 (0.81–1.09) | | 83 (32) | 1.01 (0.69–1.49) |
|
|
|
|
|
| 0.405 | ||
| Without BCG vaccination | 187 (45) | Referent |
| 26 (50) | Referent |
|
| With BCG vaccination | 853 (50) | 1.07 (0.97–1.19) |
| 139 (60) | 1.21 (0.90–1.63) | |
| Incidence† | HR (95% CI) |
| Incidence† | HR (95% CI) | ||
| Time to TST conversion |
|
|
|
|
| 0.579 |
| Without BCG vaccination | 0.18 (48/260) | Referent |
| 0.21 (7/32) | Referent |
|
| With BCG vaccination | 0.27 (292/1,065) | 1.5 (1.08–2.08) |
| 0.45 (53/119) | 1.84 (0.77–4.39) |
|
| Time to TB |
|
|
|
|
| 0.168 |
| Without BCG vaccination | 4,585 (25/545) | Referent |
| 3,098 (2/65) | Referent |
|
| With BCG vaccination | 2,619 (60/2291) | 0.58 (0.35–0.96) |
| 4,639 (13/280) | 1.96 (0.41–9.39) | |
|
| Infection prevalence, no. (%) | RR (95% CI) |
| Infection prevalence, no. (%) | RR (95% CI) |
|
| Adults, >15 y |
|
|
|
|
|
|
| Baseline |
|
|
|
| 0.611 | |
| Without BCG vaccination | 260 (47) | Referent |
| 27 (51) | Referent |
|
| With BCG vaccination | 2,263 (54) | 1.07 (0.98–1.18) |
| 313 (54) | 1.00 (0.78–1.29) |
|
|
|
|
|
| 0.315 | ||
| Without BCG vaccination | 334 (72) | Referent |
| 39 (81) | Referent |
|
| With BCG vaccination | 3,042 (82) | 1.10 (1.04–1.16) |
| 419 (82) | 1.02 (0.89–1.16) | |
| Incidence† | HR (95% CI) |
| Incidence† | HR (95% CI) | ||
| Time to TST conversion | 0.315 | |||||
| Without BCG vaccination | 0.41 (70/172) | Referent | 0.77 (10/13) | Referent | ||
| With BCG vaccination | 0.72 (728/1,020) | 1.55 (1.18–2.04) | 0.73 (105/144) | 1.00 (0.48–2.06) | ||
| Time to TB | 0.732 | |||||
| Without BCG vaccination | 4,813 (28/582) | Referent | 6,574 (4/61) | Referent | ||
| With BCG vaccination | 2,860 (129/4511) | 0.66 (0.43–1.02) | 2,434 (15/616) | 0.53 (0.17–1.68) | ||
*BCG, M. bovis BCG; HR, hazard ratio; RR, risk ratio; TB, tuberculosis; TST, tuberculin skin test. †Cases per person-year (no. converted/no. tested).